$0.33
2.19%
NYSE, Sep 17, 04:00 pm EDT. Closed.
ISIN
US98420P3082
Symbol
XTNT

Xtant Medical Target price 2026 - Analyst rating & recommendation

Xtant Medical Classifications & Recommendation

Buy
88%
Hold
13%

Xtant Medical Price Target

Target Price $1.07
Price $0.33
Potential
Number of Estimates 4
4 Analysts have issued a price target Xtant Medical 2027 . The average Xtant Medical target price is $1.07. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Xtant Medical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Xtant Medical stock has an average upside potential 2027 of . Most analysts recommend the Xtant Medical stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 133.93 102.27
14.21% 23.64%
EBITDA Margin 9.34% 2.14%
239.54% 77.09%
Net Margin 3.71% -8.39%
126.45% 326.09%

4 Analysts have issued a sales forecast Xtant Medical 2026 . The average Xtant Medical sales estimate is

$102m
unlock
. This is
6.63% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$106m 3.62%
unlock
, the lowest is
$98.0m 10.53%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $134m 14.21%
2026
$102m 23.64%
unlock
2027
$112m 9.76%
unlock
2028
$121m 7.92%
unlock
2029
$137m 13.41%
unlock
2030
$149m 8.79%
unlock
2031
$163m 8.87%
unlock

4 Analysts have issued an Xtant Medical EBITDA forecast 2026. The average Xtant Medical EBITDA estimate is

$2.2m
unlock
. This is
248.78% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$7.0m 577.69%
unlock
, the lowest is
$-2.4m 60.00%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $12.5m 259.36%
2026
$2.2m 82.52%
unlock
2027
$8.8m 304.30%
unlock
2028
$18.0m 103.78%
unlock
2029
$43.5m 141.48%
unlock
2030
$53.9m 23.89%
unlock
2031
$65.2m 20.93%
unlock

EBITDA Margin

2025 9.34% 239.54%
2026
2.14% 77.09%
unlock
2027
7.88% 268.22%
unlock
2028
14.87% 88.71%
unlock
2029
31.67% 112.98%
unlock
2030
36.07% 13.89%
unlock
2031
40.06% 11.06%
unlock

4 Xtant Medical Analysts have issued a net profit forecast 2026. The average Xtant Medical net profit estimate is

$-8.6m
unlock
. This is
22.98% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-5.9m 47.13%
unlock
, the lowest is
$-11.0m 1.26%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $5.0m 130.21%
2026
$-8.6m 272.64%
unlock
2027
$-720k 91.61%
unlock
2028
$7.2m 1,093.06%
unlock
2029
$21.5m 200.14%
unlock
2030
$31.5m 46.64%
unlock
2031
$38.6m 22.75%
unlock

Net Margin

2025 3.71% 126.45%
2026
-8.39% 326.09%
unlock
2027
-0.64% 92.37%
unlock
2028
5.90% 1,021.88%
unlock
2029
15.62% 164.75%
unlock
2030
21.06% 34.83%
unlock
2031
23.74% 12.73%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ 0.03 -0.06
125.00% 300.00%
P/E negative
EV/Sales 0.60

4 Analysts have issued a Xtant Medical forecast for earnings per share. The average Xtant Medical EPS is

$-0.06
unlock
. This is
25.00% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.04 50.00%
unlock
, the lowest is
$-0.08 0.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $0.03 125.00%
2026
$-0.06 300.00%
unlock
2027
$-0.01 83.33%
unlock
2028
$0.05 600.00%
unlock
2029
$0.15 200.00%
unlock
2030
$0.22 46.67%
unlock
2031
$0.28 27.27%
unlock

P/E ratio

Current -4.09 74.09%
2026
-5.34 30.64%
unlock
2027
-64.12 1,100.75%
unlock
2028
6.41 110.00%
unlock
2029
2.14 66.61%
unlock
2030
1.46 31.78%
unlock
2031
1.19 18.49%
unlock

Based on analysts' sales estimates for 2026, the Xtant Medical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.56 34.88%
2026
0.60 7.66%
unlock
2027
0.55 8.89%
unlock
2028
0.51 7.34%
unlock
2029
0.45 11.83%
unlock
2030
0.41 8.07%
unlock
2031
0.38 8.17%
unlock

P/S ratio

Current 0.44 31.18%
2026
0.47 7.09%
unlock
2027
0.43 8.88%
unlock
2028
0.40 7.36%
unlock
2029
0.35 11.81%
unlock
2030
0.32 8.07%
unlock
2031
0.30 8.16%
unlock

Current Xtant Medical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
LUCID CAPITAL MARKETS
Locked
Locked
Locked Sep 02 2026
BTIG
Locked
Locked
Locked May 13 2026
BTIG
Locked
Locked
Locked Mar 31 2026
BTIG
Locked
Locked
Locked Nov 11 2025
Analyst Rating Date
Locked
LUCID CAPITAL MARKETS:
Locked
Locked
Sep 02 2026
Locked
BTIG:
Locked
Locked
May 13 2026
Locked
BTIG:
Locked
Locked
Mar 31 2026
Locked
BTIG:
Locked
Locked
Nov 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today